Two novel methods for the determination of CYP1A2 activity using the paraxanthine/caffeine ratio

Fundamental and Clinical Pharmacology

Volumn 17, Issue 3, 2003, Pages 355-362

  Doude Van Troostwijk, Lous J A E ^a   Koopmans, Richard P ^a   Guchelaar, Henk Jan ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Caffeine; CYP1A2; Enzyme activity; Metabolite ratio

Indexed keywords

CAFFEINE; CYTOCHROME P450 1A2; PARAXANTHINE;

ABSTINENCE; ADULT; ARTICLE; BLOOD LEVEL; COMPARTMENT MODEL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; MALE; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL; PROVOCATION TEST; SIMULATION;

ADULT; AREA UNDER CURVE; CAFFEINE; CYTOCHROME P-450 CYP1A2; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; THEOPHYLLINE;

EID: 0038772258     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2003.00136.x     Document Type: Article

References (14)

1. Sachse C., Brockmoller J., Bauer S., Roots I. Functional significance of a C → A polymorphism in intron I of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol. (1999) 47 445-449.
2. Kalow W.K., Tang B.K. The use of caffeine for enzyme assays: a critical appraisal. Clin. Pharmacol. Ther. (1993) 53 503-514.
3. McQuilkin S.H., Nierenberg D.W., Bresnick E. Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities. Cancer Epidemiol. Biomarkers Prev. (1995) 4 139-146.
4. Denaro C.P., Brown C.R., Wilson M., Jacob P., Benowitz N.L. Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance. Clin. Pharmacol. Ther. (1996) 59 284-296
5. Fuhr U., Rost K.L. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics (1994) 4 109-116.
6. Spigset O., Hagg S., Soderstrom E., Dahlqvist R. The paraxanthine:caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: when should the sample be obtained? Pharmacogenetics (1999) 9 409-412.
7. Koch J.P., Tusscher G.W., Koppe I.G., Guchelaar H.J. Validation of a high-performance liquid chromatography assay for quantification of caffeine and paraxanthine in human serum in the context of CYP1A2 phenotyping. Biomed. Chromatogr. (1999) 13 309-314.
8. Bonati M., Latini R., Galletti F., Young J.F., Tognoni G., Garattini S. Caffeine disposition after oral doses. Clin. Pharmacol. Ther. (1982) 32 98-106.
9. Campbell M.E., Spielberg S.P., Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin. Pharmacol. Ther. (1987) 42 157-165.
10. Sheiner L.B., Beal S.L. Some suggestions for measuring predictive performance. J. Pharmacokin. and Biopharm. (1981) 9 503-512.
11. Rostami-Hodjegan A., Nurminen S., Jackson P.R., Tucker G.T. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics (1996) 6 121-149.
12. Newton R., Broughton L.J., Lind M.J., Morrison P.J., Rogers H.J., Dradbrook I.D. Plasma and salivary pharmacokinetics of caffeine in man. Eur. J. Clin. Pharmacol. (1981) 21 45-52.
13. Denaro C.P., Brown C.R., Wilson M., Jacob P., Benowitz N.L. Dose-dependency of caffeine metabolism with repeated dosing. Clin. Pharmacol. Ther. (1990) 48 277-285.
14. Nordmark A., Lundgren S., Cnattingius S., Rane A. Dietary caffeine as a probe agent for assessment of cytochrome P4501A2 activity in random urine samples. Br. J. Clin. Pharmacol. (1999) 47 397-402.